narnatumab

{{Short description|Monoclonal antibody}}

{{cs1 config|name-list-style=vanc}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 458283354

| type = mab

| image =

| alt =

| mab_type = mab

| source = o

| target = MST1R (aka RON)

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 1188275-92-4

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = R42YK40U9M

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| KEGG = D10074

| C=6454 | H=10026 | N=1754 | O=2020 | S=44

|drug_name=|caption=|licence_EU=|licence_US=}}

Narnatumab is a human monoclonal antibody designed for the treatment of cancer.{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Narnatumab|publisher=American Medical Association|url=http://www.ama-assn.org/resources/doc/usan/narnatumab.pdf | archive-url = https://web.archive.org/web/20120928203005/http://www.ama-assn.org/resources/doc/usan/narnatumab.pdf | archive-date = 28 September 2012 }} Clinical development was abandoned after phase I trials.{{cite web |title= Narnatumumab|url=http://adisinsight.springer.com/drugs/800032136 | work = AdisInsight | publisher = Springer Nature Switzerland AG |access-date=31 January 2017}}{{cite journal | vauthors = LoRusso PM, Gounder M, Jalal SI, André V, Kambhampati SR, Loizos N, Hall J, Holzer TR, Nasir A, Cosaert J, Kauh J, Chiorean EG | display-authors = 6 | title = Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors | journal = Investigational New Drugs | volume = 35 | issue = 4 | pages = 442–450 | date = August 2017 | pmid = 28161886 | pmc = 5502198 | doi = 10.1007/s10637-016-0413-0 }}

Narnatumab was developed by ImClone Systems.